Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2116 to 2130 of 8984 results

  1. Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]

    Awaiting development Reference number: GID-TA11526 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID5080]

    Awaiting development Reference number: GID-TA10967 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]

    Awaiting development Reference number: GID-TA10911 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Perioperative care in adults

    In development Reference number: GID-QS10094 Expected publication date:  01 July 2026

    Quality standard
    In development

  5. Endouterine-ultrasound guided transcervical radiofrequency ablation for fibroids

    In development Reference number: GID-HTG10470 Expected publication date: TBC

    HealthTech guidance
    In development

  6. Transvaginal radiofrequency Ablation for symptomatic uterine fibroids

    In development Reference number: GID-HTG10538 Expected publication date: TBC

    HealthTech guidance
    In development

  7. Povorcitinib for treating non-segmental vitiligo [TSID12388]

    Awaiting development Reference number: GID-TA12019 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Lonapegsomatropin for treating growth hormone deficiency in people 3 to 17 years [TSID12395]

    Awaiting development Reference number: GID-TA12013 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Grazax for treating allergic rhinitis and conjunctivitis caused by grass pollen in people 5 years and over [TSID12379]

    Awaiting development Reference number: GID-TA12010 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. GNT0006 ATA-100 for treating FKRP-related limb girdle muscular dystrophy R9 [TSID12384]

    Awaiting development Reference number: GID-TA12009 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Encaleret for treating autosomal dominant hypocalcaemia type 1 in people 16 years and over [TSID12390]

    Awaiting development Reference number: GID-TA12008 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]

    In development Reference number: GID-TA11963 Expected publication date:  13 January 2027

    Technology appraisal guidance
    In development

  13. Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils [ID1237]

    In development Reference number: GID-TA10239 Expected publication date:  06 August 2026

    Technology appraisal guidance
    In development

  14. Canakinumab for untreated Schnitzler syndrome [ID4063]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. Surovatamig for treating relapsed or refractory B-cell acute lymphoblastic leukaemia after 2 or more lines of treatment in people 12 years and over [ID6630]

    Awaiting development Reference number: GID-TA11837 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development